secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-035174
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics FY2025 net loss $20.2M ($0.61/sh); cash $20.8M; Phase 1b data supports GT-02287
--------------------------------------------------------------------------------

- Net loss $20.2M ($0.61 per share) vs $20.4M ($0.89) prior year; R&D $10.2M, G&A $8.5M.
- Cash, equivalents & marketable securities $20.8M as of Dec 31, 2025 (up from $10.4M).
- Phase 1b extension: 14 of 16 participants completed day 150; MDS-UPDRS scores stable.
- CSF GluSph decreased 81% at day 90 in elevated-baseline participants; DDC also reduced.
- IND submission for GT-02287 expected 2Q26; Phase 2 start 3Q26; Phase 1b final data 4Q26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/0001104659-26-035174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/ganx-20260326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-035174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer